This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Chediak-Higashi Syndrome / CHS / LYST gene deficiency체디아크(-스타인브링크)-히가시증후군

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E70.3 (Chediak-Higashi syndrome; same code as albinism and cross syndrome but a separate file) | OMIM: 214500 | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsChediak-Higashi syndrome (CHS), Chediak-Steinbrinck-Higashi syndrome, LYST gene deficiency, lysosomal trafficking regulator deficiency, combined syndrome of partial albinism, immunodeficiency, and neurological symptoms, OMIM #214500
C. Adult onsetLikelihood of first onset in adulthood low — most are diagnosed in childhood with recurrent bacterial infections and albinism; in some mild (adolescent/adult-onset, adolescent/adult type) forms, cases have been reported presenting for the first time in adulthood with only progressive neurological symptoms (peripheral neuropathy, ataxia, parkinsonism-like).
1. HistoryFirst described by Beguez César (Cuba) in 1943 → independently reported in 1952 by Steinbrinck (Germany), Chediak (Cuba), and Higashi (Japan) → characteristic giant granules in peripheral blood established in the 1960s–70s → LYST/CHS1 gene cloned in 1996 → HSCT established as standard in the 2000s.
2. CausesLYST (lysosomal trafficking regulator) gene (1q42.3) variants → LYST protein deficiency → abnormal size regulation of intracellular lysosomes and lysosome-related organelles (melanosomes, lytic granules, platelet dense granules, NK cell lytic granules, etc.) → formation of giant abnormal granules → dysfunction of immune cells, pigment cells, and nerve cells.
3. GeneticsAutosomal recessive. LYST gene (1q42.3), 59 exons, OMIM *606897. A very large gene with a total length of about 430 kb. More than 100 pathogenic variants reported. Nonsense and frameshift variants = severe early onset; some missense variants = mild adolescent/adult phenotype.
4. General epidemiologyWorldwide incidence about 1:1,000,000. About 500 cases reported worldwide. Reported relatively often in Latin America and the Middle East. Korea: extremely rare, only a few case reports. Equal in males and females.
5. PathophysiologyLYST deficiency → abnormal fusion and size regulation of intracellular organelles (lysosomes, melanosomes, lytic granules, platelet dense granules) → ① formation of abnormal giant granules (pathological marker), ② impaired degranulation of neutrophils, NK cells, and cytotoxic T cells → recurrent bacterial infections and risk of HLH (hemophagocytic lymphohistiocytosis), ③ melanosome abnormalities → partial albinism, ④ neuronal lysosome abnormalities → progressive neurodegeneration.
6. SymptomsPartial albinism (silvery, silver-gray hair, pale skin). Recurrent bacterial infections (Staphylococcus, Streptococcus, Pseudomonas, etc.). Bleeding tendency (nosebleeds, easy bruising). Accelerated phase/HLH: fever, hepatosplenomegaly, pancytopenia, coagulopathy. Neurological symptoms (peripheral neuropathy, ataxia, intellectual disability, parkinsonism-like findings). Photophobia and nystagmus.
7. SignsGiant cytoplasmic granules on peripheral blood smear (pathognomonic): seen in neutrophils, lymphocytes, and monocytes. Silvery hair (irregular pigment distribution on light microscopy). Hepatosplenomegaly (accelerated phase). Pancytopenia (CBC). Reduced NK cell and cytotoxic T cell function. Bone marrow examination (hemophagocytosis). Abnormal nerve conduction studies.
8. ScreeningNot included in newborn screening. Individual diagnosis based on clinical suspicion (silvery hair + recurrent infections + bleeding tendency). Peripheral blood smear (identification of giant granules) is the simplest and most specific first-line screening method. Confirm family history (consanguineous marriage, affected siblings). The key is not to miss the window for HSCT after early detection.
9. DiagnosisPeripheral blood smear (May-Grünwald-Giemsa stain): giant cytoplasmic granules (pathognomonic). Complete blood count (CBC): pancytopenia (accelerated phase). NK cell cytotoxicity testing (flow cytometry). LYST gene NGS (confirmation, family testing, prenatal diagnosis). Bone marrow examination (confirmation of hemophagocytosis). Ferritin, fibrinogen, triglycerides (HLH markers). Nerve conduction studies and brain MRI.
10. TreatmentHematopoietic stem cell transplantation (HSCT): the only curative therapy — corrects immune and hematologic abnormalities (cannot prevent neurological lesions). Accelerated phase/HLH: HLH-2004 protocol (dexamethasone, etoposide, cyclosporine). Prophylactic antibacterials and antifungals (TMP-SMX), intravenous immunoglobulin (IVIG). Live vaccines contraindicated. Neurological symptoms: symptomatic treatment (dopaminergic agents for parkinsonism-like symptoms, etc.). Bleeding management: platelet transfusion.
11. PrognosisBefore HSCT: most die before age 7 (HLH or recurrent infections). After HSCT (before the accelerated phase, HLA-matched): 5–10-year survival 50–80% or higher. However, HSCT does not prevent neurological lesions → progressive neurological complications in many long-term survivors. In the mild adolescent/adult form, survival into adulthood without HSCT is possible, but neurodegeneration progresses.
12. PreventionPrimary: genetic counseling, carrier testing, prenatal LYST genetic diagnosis. Secondary: immediate HSCT preparation after early clinical and hematologic detection (transplantation before the accelerated phase is important). Prophylactic antibacterials and antifungals. Live vaccines contraindicated (including family members). Tertiary: post-HSCT infection monitoring, follow-up of neurological symptoms, rehabilitation, psychological support for the family.
13. ReferencesIntrone W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab. 1999. and 9 other papers

1. History

The history of Chediak-Higashi syndrome begins with independent clinical reports made almost simultaneously in several countries. In 1943, Cuban pediatrician Antonio Beguez César first described a pediatric case with recurrent infections, bleeding tendency, and silvery hair, but it received little attention at the time. In 1952, W. Steinbrinck of Germany, Moisés Chediak of Cuba, and Ōtaka Higashi of Japan each independently reported similar cases characterized by abnormal giant granules in leukocytes. The name "Chediak-Higashi syndrome (CHS)" was established after these reporters, and including Steinbrinck's contribution it is also called "Chediak-Steinbrinck-Higashi syndrome" (OMIM #214500).

In the 1960s–70s, the pathological giant cytoplasmic granules seen in neutrophils, lymphocytes, and monocytes on peripheral blood smears were established as the diagnostic marker of CHS. These giant granules result from abnormal fusion and enlargement of normal lysosomes and became a key clue to understanding the pathology of CHS. In the 1980s–90s, studies using animal models with CHS-like phenotypes (beige mice, mink, Icelandic horses, etc.) contributed greatly to research on its pathogenesis.

In 1996, Nagle et al. and Perou et al. each identified the LYST (lysosomal trafficking regulator, or CHS1) gene in Nature Genetics, first establishing the molecular cause of CHS (PMID: 8673133). The LYST gene is located on the long arm of chromosome 1 (1q42.3) and encodes a large protein that regulates the size and sorting of intracellular lysosomes and related organelles. These studies demonstrated the mechanism by which loss of LYST protein function causes dysregulated fusion of intracellular organelles, forming giant abnormal granules.

An important turning point in the history of treatment was the introduction of hematopoietic stem cell transplantation (HSCT). From the 1980s, it was reported that bone marrow transplantation from HLA-matched sibling donors could correct the immunological complications of CHS, and indications were later expanded to unrelated donor transplantation and cord blood transplantation. HSCT is now recognized as the only curative therapy for CHS, and performing transplantation before the accelerated phase (AP) provides the best prognosis.

In genotype–phenotype correlation studies, nonsense and frameshift variants of the LYST gene cause complete loss of protein, producing a severe childhood-onset phenotype, whereas some missense variants retain residual LYST protein function, causing "adolescent/adult-onset CHS" in which patients survive with relatively mild disease into adolescence or adulthood. In Korea, a few CHS cases have been reported in pediatric hematology-oncology, with LYST gene variants confirmed in some.


2. Causes

Chediak-Higashi syndrome is an autosomal recessive immunodeficiency disease caused by pathogenic variants of the LYST (lysosomal trafficking regulator, or CHS1) gene (1q42.3). The LYST protein plays a key role in the size regulation, trafficking, and intracellular membrane fusion of lysosomes and lysosome-related organelles (LROs) within the cell.

The LYST protein is a very large cytoplasmic protein of about 3,801 amino acids (molecular weight about 430 kDa), with a complex structure including a HEAT repeat domain, an Armadillo (ARM) repeat domain, a BEACH domain (beige and Chediak-Higashi domain), and WD40 repeats. LYST is thought to interact with Rab GTPases and SNARE complexes to regulate the trafficking and fusion of intracellular organelles. When LYST function is lost, size regulation of various LROs fails, and abnormally large giant granules form.

The organelles affected as a result of LYST deficiency, and the consequences, are as follows.


3. Genetics

Chediak-Higashi syndrome follows autosomal recessive inheritance. The causative gene LYST (OMIM *606897) is located on the long arm of chromosome 1 at q42.3 and, with 59 exons and a genomic length of about 430 kb, is one of the largest genes in the human genome. The mRNA is about 13.5 kb long, and the mature protein has 3,801 amino acids.

More than 100 LYST variants have been reported in the literature and databases (ClinVar, HGMD) worldwide. Variant types include nonsense variants, frameshifts (insertions/deletions), splicing variants, missense variants, and large deletions. There is an important genotype–phenotype correlation between variant type and clinical phenotype. Nonsense or frameshift variants produce no complete LYST protein because of premature termination codons, causing a severe childhood-onset phenotype (severe immunodeficiency, early accelerated phase, early death). In contrast, some missense variants retain residual LYST function and cause a mild "adolescent/adult-onset" phenotype; in this case patients survive into adulthood without severe immunodeficiency, but progressive neurological symptoms (peripheral neuropathy, ataxia, parkinsonism-like) become the main clinical problem.

In genetic counseling, carrier parents are clinically asymptomatic, and the recurrence risk for children is 25%. Because the LYST gene is very large and the variant spectrum is broad, full gene sequencing or an NGS-based immunodeficiency panel is recommended for molecular diagnosis. After confirmation, carrier testing within the family and prenatal genetic diagnosis in subsequent pregnancies (chorionic villus sampling or amniocentesis) are possible.

Molecular genetic differentiation from clinically similar conditions (Hermansky-Pudlak syndrome, Griscelli syndrome, cross syndrome, etc.) is important. Differentiation from Griscelli syndrome (RAB27A or MYO5A gene variants) is particularly important clinically; they are distinguished by the presence of giant granules on peripheral blood smear (specific to CHS, absent in Griscelli) and by hair microscopy findings (CHS: irregular pigment distribution; Griscelli type 2: pigment clumping).


4. General epidemiology

Chediak-Higashi syndrome is an extremely rare disease with a worldwide incidence of about 1:1,000,000. Since the first report in 1943, about 500 cases have been reported in the literature worldwide through the 2020s. The sex distribution is equal (a feature of autosomal recessive inheritance), and it is known to occur in all races and ethnic groups.

In terms of geographic distribution, relatively more cases have been reported in Latin America (Mexico, Cuba, etc.) and the Middle East, which is interpreted as reflecting differences in the frequency of consanguineous marriage and in reporting practices. Sporadic cases are also reported in South Asian (India, Pakistan) and Middle Eastern Arab populations.

In Korea it is an extremely rare disease, with only a few cases reported in the literature. Cases of CHS diagnosed in children with recurrent infections and silvery hair have been reported intermittently in pediatric hematology-oncology and immunology in Korea, and LYST gene variants were confirmed molecularly in some. In Korea it is registered under Special Copayment Reduction V117 (rare disease).

The pattern of higher incidence in populations with relatively frequent consanguineous marriage is consistent with autosomal recessive inheritance. Because it is not included in newborn screening, most diagnoses are made from the clinical clues of recurrent bacterial infections or silvery hair. Because diagnosis and HSCT before the accelerated phase are far more favorable for prognosis, early recognition and a rapid diagnostic system are important.


5. Pathophysiology

The core pathophysiology of CHS is dysregulated size and trafficking of intracellular organelles due to loss of LYST protein function. This abnormality damages the immune, pigmentary, and nervous systems in different ways.

Immune dysfunction: in LYST deficiency, degranulation of the cytotoxic granules (lytic granules, containing perforin and granzyme) of NK cells and CTLs proceeds abnormally. The abnormal giant granules cannot approach target cells and fuse with and be released at the cell membrane normally. As a result, the cytotoxic activity of NK cells is markedly reduced, and immune surveillance fails, particularly against the herpesvirus family including EBV. EBV infection becomes the main trigger of the accelerated phase/hemophagocytic lymphohistiocytosis (HLH). In neutrophils as well, phagolysosome formation and oxidative bactericidal mechanisms are impaired, resulting in recurrent bacterial infections.

Pigmentary abnormalities: in melanocytes, normal breakdown and redistribution of melanosomes do not occur, so melanosomes become abnormally enlarged and form clusters. This appears on light microscopy as irregular pigment distribution (the pathological basis of silvery, grayish-white hair) and causes partial hypopigmentation of the skin and iris.

Bleeding tendency: deficiency of platelet dense granules (containing ADP and serotonin) impairs platelet aggregation. This causes bruising, nosebleeds, and excessive bleeding. Platelet counts may initially be normal but progress to pancytopenia in the accelerated phase.

Neurodegeneration: in neurons, LYST deficiency causes neuronal lysosomal dysfunction, leading to accumulation of abnormal material and formation of large inclusions in neuronal cell bodies and axons. This neurodegenerative process is an independent pathology that continues to progress even after immune and hematologic abnormalities are corrected by HSCT, and it causes progressive neurological complications in long-term HSCT survivors.

Accelerated phase (HLH): EBV or other infectious triggers cause uncontrolled activation of T lymphocytes and macrophages, producing an excessive cytokine storm (IFN-γ, TNF-α, etc.), and hemophagocytosis, hepatosplenomegaly, pancytopenia, hyperferritinemia, coagulopathy, and multiorgan failure progress rapidly. This is the main cause of early death in untreated CHS.


6. Symptoms

The clinical symptoms of CHS fall into three broad groups: pigmentary abnormalities, recurrent infections and bleeding, and neurological symptoms.

Pigmentary abnormalities: partial oculocutaneous albinism is characteristic. The skin is pale and the hair silvery or grayish-white (silvery hair is the key clinical clue to CHS), and the eyelashes may also be silvery. The iris is blue-gray and sensitive to light (photophobia). Nystagmus may be present. The pigmentary abnormality of skin and hair is partial hypopigmentation rather than complete absence of pigment, with more pigment remaining than in OCA1A.

Recurrent infections: bacterial skin infections (impetigo, boils), pneumonia, sinusitis, otitis media, sepsis, and the like recur, beginning in the first months of life. The main pathogens are Staphylococcus aureus, Streptococcus, and Pseudomonas aeruginosa. Susceptibility to fungi and some viruses (especially the herpesvirus family) is also increased.

Bleeding tendency: because of platelet dense granule deficiency, bruising occurs easily, nosebleeds are frequent, and excessive bleeding occurs with surgery or trauma. Platelet counts may initially be normal.

Accelerated phase/HLH: about 85% of CHS patients experience the accelerated phase before age 10. Persistent fever, hepatosplenomegaly, lymphadenopathy, pancytopenia, and coagulopathy develop rapidly. EBV infection is the main trigger, and without treatment it rapidly worsens, leading to multiorgan failure and death.

Neurological symptoms: progressive peripheral neuropathy (sensory and motor decline), cerebellar ataxia, seizures, cognitive decline, and parkinsonism-like symptoms appear. This is an independent pathology that progresses even after HSCT. Neurological symptoms are the main phenotype in the adolescent/adult-onset form.


7. Signs

The most important pathological sign of CHS is giant cytoplasmic granules on peripheral blood smear.

Giant granules on peripheral blood smear (pathognomonic): on May-Grünwald-Giemsa or Wright-Giemsa stained smears, abnormal giant granules of various sizes are seen in the cytoplasm of neutrophils, lymphocytes, monocytes, and eosinophils. This finding is pathologically specific to CHS and is the simplest and most decisive test for diagnosis.

Silvery hair (light microscopy findings): on light microscopy of hair, an abnormal pigment distribution in irregular clusters is seen instead of the normal even distribution. This finding is distinguished from the pigment clumping of Griscelli syndrome.

Blood test abnormalities (accelerated phase): pancytopenia (anemia, leukopenia, thrombocytopenia). Markedly elevated serum ferritin (often >10,000 ng/mL), elevated triglycerides, decreased fibrinogen (HLH diagnostic criteria).

Hepatosplenomegaly: enlarged liver and spleen on physical examination. Prominent in the accelerated phase. Confirmed by abdominal ultrasound or CT.

Reduced NK cell function: marked reduction in NK cell number or function on flow cytometry and NK cell cytotoxicity testing (chromium release assay or flow-based assay).

Abnormal nerve conduction studies and brain MRI: reduced nerve conduction velocity and amplitude in patients with peripheral neuropathy. Brain MRI shows cerebellar atrophy, brain atrophy, and white matter abnormalities in long-term survivors.


8. Screening

CHS is not a target of standard newborn screening, because no specific metabolite or blood biomarker is included among the standard screening items. Early detection therefore relies on clinical suspicion and a simple blood smear.

Individual diagnosis based on clinical suspicion: when the following combination is observed, CHS should be suspected immediately and testing performed: ① silvery to grayish-white hair (partial albinism), ② recurrent bacterial infections (especially skin, lungs), ③ bleeding tendency (bruising, nosebleeds). This combination of three is highly characteristic of CHS.

Peripheral blood smear: the simplest and most specific first-line screening test. A May-Grünwald-Giemsa stained smear is prepared to check for giant granules in the cytoplasm of neutrophils and lymphocytes. Positive giant granules strongly suggest CHS and call for immediate confirmatory testing (LYST genetic testing) and referral to a specialist center.

Confirmation of family history: check for consanguineous marriage, affected siblings, and a family history of early death of children with a similar clinical picture.

Prevention of HLH triggers: in patients suspected of CHS, early detection and treatment of EBV and other herpesvirus infections are important for preventing the accelerated phase. With fever of unknown origin or sudden deterioration, HLH protocol testing is performed immediately.


9. Diagnosis

Confirmation of CHS is made by peripheral blood smear findings and LYST gene molecular testing.

Peripheral blood smear (May-Grünwald-Giemsa stain): identification of abnormal giant granules in the cytoplasm of neutrophils, lymphocytes, and monocytes is the pathologically specific finding of CHS. This finding alone strongly supports the clinical diagnosis and allows immediate clinical decision-making before further molecular testing.

LYST gene molecular genetic testing (NGS): pathogenic variants are identified by full sequencing of the LYST gene (1q42.3) + exon deletion/duplication analysis (MLPA or CNV-NGS). If LYST is included in a primary immunodeficiency NGS panel, panel testing is also possible. Molecular confirmation is essential for genetic counseling, family carrier testing, and prenatal diagnosis.

NK cell function testing: absolute NK cell (CD56+CD3-) count by flow cytometry. NK cell degranulation testing (CD107a degranulation assay): degranulation capacity is assessed by the degree of CD107a surface expression after target cell stimulation. NK cell degranulation is markedly reduced in CHS.

Whether the diagnostic criteria for the accelerated phase/HLH are met: fever, splenomegaly, cytopenias (≥2 lineages), serum ferritin ≥500 ng/mL, triglycerides ≥265 mg/dL or fibrinogen ≤150 mg/dL, hemophagocytosis (bone marrow, liver, or spleen specimen), reduced NK cell function, soluble CD25 (sCD25) ≥2,400 U/mL (HLH-2004 criteria, 5 or more of 8 items met).

Bone marrow examination: in the accelerated phase, hemophagocytosis is confirmed on bone marrow smear. Giant granules in granulocytes can also be seen on bone marrow examination.

Neurological evaluation: nerve conduction studies (evaluation of peripheral neuropathy), brain MRI (cerebellar and brain atrophy, white matter abnormalities). Performed periodically in patients with neurological symptoms.


10. Treatment

Treatment of CHS is broadly divided into HSCT, the curative therapy, and supportive care to control infections and the accelerated phase until HSCT.

Hematopoietic stem cell transplantation (HSCT): currently the only curative therapy for CHS. Successful HSCT restores normal hematopoiesis, correcting the problems of immunodeficiency, bleeding tendency, and recurrent infections. The ideal donor is a fully HLA-matched sibling, but alternative unrelated donor transplantation and umbilical cord blood transplantation are also possible. Timing of HSCT: performing it before the accelerated phase, preferably in a stable chronic phase, is far more favorable for prognosis. Transplantation after the accelerated phase markedly increases transplant-related complications and mortality. Caution: HSCT does not correct neurological lesions. Neurodegeneration may continue to progress even after HSCT.

Treatment of the accelerated phase/HLH (HLH-2004 protocol): when the accelerated phase occurs, combination therapy with dexamethasone, etoposide (VP-16), and cyclosporine is given according to the HLH-2004 protocol. This treatment suppresses the accelerated phase and serves as a bridge to HSCT. In EBV-related accelerated phase, rituximab may be added.

Prophylactic treatment: TMP-SMX (trimethoprim-sulfamethoxazole) is given prophylactically to prevent bacterial infections. Fungal prophylaxis is given with antifungals such as fluconazole. Intravenous immunoglobulin (IVIG) compensates for antibody deficiency. Live vaccines (live attenuated vaccines, e.g., BCG, varicella, MMR live vaccines) are absolutely contraindicated, and when siblings in the family receive live vaccines, care is needed regarding their contact with the patient.

Management of neurological symptoms: there is currently no treatment that prevents neurodegeneration itself. Physical therapy and assistive devices for peripheral neuropathy. Trial use of dopaminergic drugs (L-DOPA, etc.) for parkinsonism-like symptoms has been reported in some cases.

Bleeding management: platelet transfusion for active bleeding. For severe bleeding, fresh frozen plasma (FFP), cryoprecipitate, and the like are used.


11. Prognosis

The prognosis of CHS differs greatly depending on the timing and method of treatment.

Before HSCT: about 85% of patients with severe childhood-onset CHS who are untreated or receive only supportive care experience the accelerated phase (HLH) before age 10, and without treatment most die before age 7. Causes of death are recurrent bacterial infections, multiorgan failure due to the accelerated phase, and bleeding.

After HSCT (before the accelerated phase, HLA-matched donor): when HSCT from a fully HLA-matched donor is performed in a stable chronic phase (before the accelerated phase), 5–10-year survival of 50–80% or higher is reported. HSCT effectively corrects immunodeficiency, bleeding tendency, and recurrent infections. Improved survival is also being reported with unrelated donor transplantation.

Limitation of HSCT regarding neurological complications: HSCT corrects immune and hematologic abnormalities but does not prevent neurodegeneration. In many long-term HSCT survivors, progressive neurological complications such as peripheral neuropathy, ataxia, and cognitive decline appear years to decades later. This is an unresolved long-term clinical problem in CHS.

Mild adolescent/adult-onset form: patients with some missense variants survive into adulthood without immunodeficiency, but progressive neurological symptoms (parkinsonism-like, ataxia) become the main cause of disability. The role of HSCT in this group has not yet been clearly established.

Overall, short-term survival in CHS has improved greatly with early diagnosis, HSCT before the accelerated phase, and appropriate prophylactic antimicrobial treatment, but prevention and treatment of neurological complications remain the key challenge for future research.


12. Prevention

Prevention of CHS operates at three levels: genetic prevention, timely HSCT after early diagnosis, and prevention of infections and the accelerated phase.

Primary prevention: LYST gene carrier testing and genetic counseling for the families of confirmed patients. In subsequent pregnancies, affected fetuses can be detected early by prenatal LYST genetic diagnosis (chorionic villus sampling or amniocentesis). Avoidance of consanguineous marriage is recommended (a general primary prevention principle for autosomal recessive genetic diseases).

Secondary prevention (early detection and HSCT): the key is to recognize the clinical triad of silvery hair + recurrent infections + bleeding tendency and immediately perform a peripheral blood smear. If giant granules are found, refer immediately to a specialist center to begin molecular diagnosis and HSCT preparation. Performing transplantation before the accelerated phase is the most important factor in improving long-term prognosis. Give prophylactic antimicrobials to prevent infection and observe the contraindication to live vaccines.

Tertiary prevention (minimizing complications): monitoring and prevention of infection after HSCT. Regular neurological evaluation (nerve conduction studies, brain MRI, neurology consultation). Rehabilitation (physical therapy, occupational therapy). Psychosocial support and family education. Post-transplant care including monitoring of donor-specific antibodies (DSA). Sun protection (skin protection related to partial albinism).


13. References

  1. Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab. 1999;68(2):283-303. DOI: 10.1006/mgme.1999.2927
  2. Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet. 1996;14(3):307-311. DOI: 10.1038/ng1196-307
  3. Barbosa MD, Nguyen QA, Tchernev VT, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature. 1996;382(6588):262-265. DOI: 10.1038/382262a0
  4. Kaplan J, De Domenico I, Ward DM. Chediak-Higashi syndrome. Curr Opin Hematol. 2008;15(1):22-29. DOI: 10.1097/MOH.0b013e3282f2bcce
  5. Eapen M, DeLaat CA, Baker KS, et al. Hematopoietic cell transplantation for Chediak-Higashi syndrome. Bone Marrow Transplant. 2007;39(7):411-415. DOI: 10.1038/sj.bmt.1705614
  6. Tardieu M, Lacroix C, Neven B, et al. Progressive neurological dysfunction 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome. Blood. 2005;106(1):40-42. DOI: 10.1182/blood-2005-01-0319
  7. Westbroek W, Adams D, Huizing M, et al. Cellular defects in Chediak-Higashi syndrome correlate with the molecular genotype and clinical phenotype. J Invest Dermatol. 2007;127(11):2674-2677. DOI: 10.1038/sj.jid.5700899
  8. Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21(5):245-253. DOI: 10.1016/j.blre.2007.05.001
  9. Boxer LA, Watanabe AM, Rister M, et al. Correction of leukocyte function in Chediak-Higashi syndrome by ascorbate. N Engl J Med. 1976;295(19):1041-1045. DOI: 10.1056/NEJM197611042951903
  10. Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. 2017;49:20-26. DOI: 10.1016/j.coi.2017.08.004